Dirk Rades

ORCID: 0000-0002-3221-7541
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Brain Metastases and Treatment
  • Management of metastatic bone disease
  • Glioma Diagnosis and Treatment
  • Head and Neck Cancer Studies
  • Spine and Intervertebral Disc Pathology
  • Lung Cancer Research Studies
  • Spinal Fractures and Fixation Techniques
  • Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Cancer Genomics and Diagnostics
  • Head and Neck Surgical Oncology
  • Chromatin Remodeling and Cancer
  • Cancer survivorship and care
  • Effects of Radiation Exposure
  • Esophageal Cancer Research and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Neuroblastoma Research and Treatments
  • Breast Cancer Treatment Studies
  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Erythropoietin and Anemia Treatment

University of Lübeck
2016-2025

University Hospital Schleswig-Holstein
2016-2025

University of the Basque Country
2025

University Medical Center
2018-2024

Helios Hospital Schwerin
2024

University of Southern Denmark
2024

Universitätsklinik für Strahlentherapie
2010-2024

Health Sciences Centre
2024

Sunnybrook Health Science Centre
2024

Leiden University
2024

PurposeTo systematically review the evidence for radiotherapeutic and surgical management of patients newly diagnosed with intraparenchymal brain metastases.Methods MaterialsKey clinical questions to be addressed in this evidence-based Guideline were identified. Fully published randomized controlled trials dealing metastases searched reviewed. The U.S. Preventative Services Task Force levels used classify various options management.ResultsThe choice single or multiple depends on estimated...

10.1016/j.prro.2011.12.004 article EN cc-by-nc-nd Practical Radiation Oncology 2012-01-31

Purpose To study five radiotherapy (RT) schedules and potential prognostic factors for functional outcome in metastatic spinal cord compression (MSCC). Patients Methods One thousand three hundred four patients who were irradiated from January 1992 to December 2003 included this retrospective review. The of 1 × 8 Gy day (n = 261), 5 4 week 279), 10 3 2 weeks 274), 15 2.5 233), 20 257) compared motor function, ambulatory status, in-field recurrences. following investigated: age, sex,...

10.1200/jco.2005.04.754 article EN Journal of Clinical Oncology 2005-05-20

Purpose To evaluate potential prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression (MSCC). Patients Methods The following were investigated retrospectively in 1,852 patients irradiated MSCC: age, sex, performance status, primary tumor, interval between tumor diagnosis MSCC (≤ 15 v > months), number involved vertebrae (one to two ≥ three), other bone metastases, visceral pretreatment ambulatory time developing motor deficits before...

10.1200/jco.2005.05.0542 article EN cc-by Journal of Clinical Oncology 2006-07-18

The appropriate treatment for MSCC is controversial. A small randomized trial showed that decompressive surgery followed by radiotherapy was superior to alone. That study limited highly selected patients. Additional studies comparing plus could better clarify the role of surgery.Data from 108 patients receiving were matched 216 (1:2) Groups 11 potential prognostic factors and compared post-treatment motor function, ambulatory status, regaining local control, survival. Subgroup analyses...

10.1200/jco.2010.28.5635 article EN Journal of Clinical Oncology 2010-07-07

Purpose To compare short-course radiotherapy (RT) (4 Gy × 5) to longer-course RT (3 10) for metastatic epidural spinal cord compression (MESCC). Patients and Methods Two-hundred three patients with MESCC poor intermediate expected survival were randomly assigned 4 5 in 1 week (n = 101) or 3 10 2 weeks 102). stratified according ambulatory status, time developing motor deficits, primary tumor type. Seventy-eight 77 patients, respectively, evaluable the end point, 1-month overall response...

10.1200/jco.2015.64.0862 article EN Journal of Clinical Oncology 2016-01-05

Hypo-fractionated radiotherapy (HF-RT) is gaining popularity in prostate cancer treatment. HF-RT can lead to cystitis, particularly cases with small bladder volumes. This study evaluated the volume during a course of moderate HF-RT. knowledge required for protocol prospective trial. Seventy-six patients receiving (20×3.0 Gy) were retrospectively evaluated. The number sessions <200 ml and corresponding risk factors investigated. Mean median numbers 13.4 (±6.7) 16.0 (interquartile...

10.21873/anticanres.17458 article EN cc-by-nc-nd Anticancer Research 2025-01-31

Abstract BACKGROUND. The current study was performed to create a scoring system estimate the survival of patients with metastatic spinal cord compression (MSCC). METHODS. Based on multivariate analysis 1852 who were treated radiotherapy (RT) for MSCC, developed. included 6 prognostic factors found be significant in that analysis: tumor type, interval between diagnosis and other bone or visceral metastases at time RT, ambulatory status, duration motor deficits. score each factor determined by...

10.1002/cncr.23150 article EN Cancer 2007-10-19

The objective of this study was to compare stereotactic radiosurgery (SRS) alone with resection plus whole-brain radiotherapy (WBRT) for the treatment patients in recursive partitioning analysis (RPA) class 1 and 2 who had or brain metastases.Two hundred six RPA metastases were analyzed retrospectively. Patients Group A (n = 94) received from 18 grays (Gy) 25 Gy SRS, B 112) underwent their 10 x 3 Gy/20 WBRT. Eight other potential prognostic factors evaluated regarding overall survival (OS),...

10.1002/cncr.22729 article EN Cancer 2007-05-08

Based on an analysis of 1852 retrospectively evaluated patients with metastatic spinal cord compression (MSCC), a scoring system was developed to predict survival. This study performed validate the in new data set.The score included 6 prognostic factors: tumor type, interval between diagnosis and MSCC, other bone or visceral metastases, ambulatory status, duration motor deficits. Scores ranged 20 45 points, were initially divided into 5 groups: those 25 26 30 31 35 36 40 41 points. To...

10.1002/cncr.25223 article EN Cancer 2010-04-30
Coming Soon ...